Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ACADIA Pharmaceuticals Inc. - Common Stock
(NQ:
ACAD
)
20.61
-0.66 (-3.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,553,287
Open
21.41
Bid (Size)
20.08 (100)
Ask (Size)
20.52 (900)
Prev. Close
21.27
Today's Range
20.54 - 21.57
52wk Range
13.40 - 28.35
Shares Outstanding
162,625,379
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
March 12, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
March 03, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Performance
YTD
-21.6%
-21.6%
1 Month
-8.3%
-8.3%
3 Month
-24.1%
-24.1%
6 Month
-12.7%
-12.7%
1 Year
+22.8%
+22.8%
More News
Read More
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
↗
March 03, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
March 02, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Surpasses $1 Billion Revenue Milestone in 2025, Beats Q4 EPS Estimates
↗
February 25, 2026
Via
Chartmill
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Emerges as a Value Stock with Strong Fundamentals
↗
February 06, 2026
Via
Chartmill
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
↗
March 02, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
↗
March 02, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts
↗
February 27, 2026
Via
Stocktwits
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup
↗
January 16, 2026
Via
Chartmill
ACADIA (ACAD) Q4 2025 Earnings Call Transcript
↗
February 25, 2026
Via
The Motley Fool
Topics
Earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
February 25, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
February 23, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
↗
February 23, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%
↗
February 23, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
February 04, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACAD Stock Slumps 8% After Hours On Hurdle To EU Approval For Genetic Disorder Drug
↗
February 02, 2026
Via
Stocktwits
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
February 02, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
January 13, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
December 30, 2025
Via
MarketMinute
Topics
ETFs
Economy
World Trade
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup for Breakout
↗
December 25, 2025
Via
Chartmill
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
December 18, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
December 12, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?
↗
December 03, 2025
Via
The Motley Fool
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms
↗
December 03, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Frequently Asked Questions
Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?
ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?
The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market
What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 20.61
When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 03/13/26 04:00 PM ET
What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 3.35B
How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
ACADIA Pharmaceuticals Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.